Infinity Pharma: Second top pct gainer on Nasdaq Biotech index after earnings results
30/03/2022 18:17
** Drug developer's shares INFI.O up 25% at $1.24; Stock
is top pct gainer on the Nasdaq Biotech index .NBI
** Says expects to start large clinical study testing its
experimental cancer drug by the end of 2022
** Expects to have cash for at least 12 months from the
filing of its annual report
** More than 2.4 mln shares traded, 4x 25-day moving average
volume; stock's busiest day since Jan
** INFI down 56% YTD through Tues close vs 10% decline in
Nasdaq biotech index
(Reporting by Ankur Banerjee)
Recent news on Infinity Pharmaceuticals
See all newsBrief: Infinity Pharmaceuticals Filed Voluntary Petition For Relief Under Provisions Of Chapter 11
Brief: Infinity Pharmaceuticals Inc Received Determination Letter From Nasdaq On September 12
Brief: Infinity Pharma Says On Sept 5, 2023, Co Received Letter From Nasdaq Notifying That Listing Of Common Stock Was Not In Compliance With Nasdaq Listing Rule
Brief: Infinity Pharmaceuticals Approved Plan To Reduce Co's Overall Headcount By 21 Positions
U.S. STOCKS ON THE MOVE-General Motors, Estee Lauder, IMAX